Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Antibodies, Monoclonal, Humanized/therapeutic use"" wg kryterium: Temat


Tytuł :
Dupilumab Treatment in Atopic Dermatitis: Real-World Evidence from a Portuguese Tertiary Center
Autorzy :
Tomás Pessoa e Costa
B. Duarte
M. Caldeira
M. Rocha Páris
M. J. Paiva-Lopes
Pokaż więcej
Temat :
Antibodies, Monoclonal, Humanized/therapeutic use
Dermatitis, Atopic/drug therapy
Dupilumab
Dermatology
RL1-803
Infectious and parasitic diseases
RC109-216
Źródło :
Revista da Sociedade Portuguesa de Dermatologia e Venereologia, Vol 79, Iss 2 (2021)
Opis pliku :
electronic resource
Relacje :
https://revista.spdv.com.pt/index.php/spdv/article/view/1318; https://doaj.org/toc/2182-2395; https://doaj.org/toc/2182-2409
Dostęp URL :
https://doaj.org/article/5cff0e5349b04138b80d5cdb43c98f37
Czasopismo naukowe
Tytuł :
RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.
Autorzy :
Hirano, I.
Collins, M.H.
Assouline-Dayan, Y.
Evans, L.
Gupta, S.
Schoepfer, A.M.
Straumann, A.
Safroneeva, E.
Grimm, M.
Smith, H.
Tompkins, C.A.
Woo, A.
Peach, R.
Frohna, P.
Gujrathi, S.
Penenberg, D.N.
Li, C.
Opiteck, G.J.
Olson, A.
Aranda, R.
Rothenberg, M.E.
Dellon, E.S.
Pokaż więcej
Temat :
Antibodies, Monoclonal/therapeutic use
Antibodies, Monoclonal, Humanized/therapeutic use
Biopsy, Needle
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Eosinophilic Esophagitis/diagnosis
Eosinophilic Esophagitis/drug therapy
Eosinophilic Esophagitis/pathology
Esophagoscopy/methods
Female
Humans
Immunohistochemistry
Interleukin-13/immunology
Internationality
Male
Patient Safety
Reference Values
Severity of Illness Index
Treatment Outcome
Esophagus
Immune Response
Placebo-Controlled
Randomized
610 Medicine & health
360 Social problems & social services
Źródło :
Hirano, Ikuo; Collins, Margaret H; Assouline-Dayan, Yehudith; Evans, Larry; Gupta, Sandeep; Schoepfer, Alain M; Straumann, Alex; Safroneeva, Ekaterina; Grimm, Michael; Smith, Heather; Tompkins, Cindy-Ann; Woo, Amy; Peach, Robert; Frohna, Paul; Gujrathi, Sheila; Penenberg, Darryl N; Li, Caiyan; Opiteck, Gregory J; Olson, Allan; Aranda, Richard; ... (2019). RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis. Gastroenterology, 156(3), 592-603.e10. Elsevier 10.1053/j.gastro.2018.10.051
Gastroenterology, vol. 156, no. 3, pp. 592-603.e10
Opis pliku :
application/pdf
Tytuł :
Cholestatic liver injury as a side-effect of dabigatran and the use of coagulation tests in dabigatran intoxication and after reversal by idarucizumab in bleeding and sepsis
Autorzy :
Comuth, Willemijn J
Haase, Anne-Mette
Henriksen, Linda Ø
Malczynski, Jerzy
van de Kerkhof, Daan
Münster, Anna-Marie B
Pokaż więcej
Temat :
Journal Article
Antidotes
blood coagulation
prothrombin time
haemorrhage
international normalized ratio
thrombin time
chemical and drug induced liver injury
activated partial thromboplastin time
blood coagulation tests
anticoagulants
dabigatran
sepsis
Hemorrhage/drug therapy
Sepsis/drug therapy
Humans
Dabigatran/adverse effects
Fatal Outcome
Gastrointestinal Hemorrhage/chemically induced
Female
Liver/injuries
Cholestasis/blood
Thrombelastography
Antibodies, Monoclonal, Humanized/therapeutic use
Blood Coagulation Tests
Aged
Źródło :
Comuth, W J, Haase, A-M, Henriksen, L Ø, Malczynski, J, van de Kerkhof, D & Münster, A-M B 2018, ' Cholestatic liver injury as a side-effect of dabigatran and the use of coagulation tests in dabigatran intoxication and after reversal by idarucizumab in bleeding and sepsis ', Scandinavian Journal of Clinical & Laboratory Investigation, vol. 78, no. 1-2, pp. 1-5 . https://doi.org/10.1080/00365513.2017.1402127
Tytuł :
Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO
Autorzy :
Kressig, Reto W
Meier, Christian
Lippuner, Kurt
Aubry-Rozier, Bérengère
Bischoff-Ferrari, Heike A
Suhm, Norbert
Stute, Petra
Birkhäuser, Martin
Uebelhart, Brigitte
Lamy, Olivier
Ferrari, Serge
Frey, Diana
Pokaż więcej
Temat :
610 Medicine & health
ddc:616
Antibodies, Monoclonal, Humanized/therapeutic use
Bone Density Conservation Agents/therapeutic use
Denosumab/therapeutic use
Diphosphonates/therapeutic use
Evidence-Based Practice
Female
Humans
Osteoporosis/drug therapy
Osteoporotic Fractures/prevention & control
Risk Factors
Time Factors
Rheumatology Clinic and Institute of Physical Medicine
Clinic for Geriatric Medicine
Źródło :
Meier, Christian; Uebelhart, Brigitte; Aubry-Rozier, Bérengère; Birkhäuser, Martin; Bischoff-Ferrari, Heike A; Frey, Diana; Kressig, Reto W; Lamy, Olivier; Lippuner, Kurt; Stute, Petra; Suhm, Norbert; Ferrari, Serge (2017). Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO. Swiss medical weekly, 147(w14484), w14484. EMH Schweizerischer Ärzteverlag 10.4414/smw.2017.14484
Swiss medical weekly, vol. 147, pp. w14484
Meier, Christian; Uebelhart, Brigitte; Aubry-Rozier, Bérengère; Birkhäuser, Martin; Bischoff-Ferrari, Heike A; Frey, Diana; Kressig, Reto W; Lamy, Olivier; Lippuner, Kurt; Stute, Petra; Suhm, Norbert; Ferrari, Serge (2017). Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO. Swiss Medical Weekly, 147:w14484.
Swiss Medical Weekly, Vol. 147, No w14484 (2017)
Opis pliku :
application/pdf
Tytuł :
Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model
Autorzy :
Jespersen, Henrik
Lindberg, Mattias F.
Donia, Marco
Söderberg, Elin M. V.
Andersen, Rikke
Keller, Ulrich
Ny, Lars
Svane, Inge Marie
Nilsson, Lisa M.
Nilsson, Jonas A.
Pokaż więcej
Temat :
Immunotherapy, Adoptive
Mice, Knockout
Article
Research Support, Non-U.S. Gov't
Cell Line, Tumor
T-Lymphocytes/immunology
Interleukin Receptor Common gamma Subunit/genetics
Antineoplastic Agents/therapeutic use
Interleukin-2/genetics
Skin Neoplasms/immunology
Science
Antibodies, Monoclonal, Humanized/therapeutic use
Neoplasm Metastasis
Journal Article
Animals
Humans
Lymphocytes, Tumor-Infiltrating/immunology
Melanoma/immunology
Źródło :
Nature Communications, Vol 8, Iss 1, Pp 1-10 (2017)
Jespersen, H, Lindberg, M F, Donia, M, Söderberg, E M V, Andersen, R, Keller, U, Ny, L, Svane, I M, Nilsson, L M & Nilsson, J A 2017, ' Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model ', Nature Communications, vol. 8, 707 . https://doi.org/10.1038/s41467-017-00786-z
Opis pliku :
application/pdf
Tytuł :
Unexpected cross-reactivity of anti-cathepsin B antibodies leads to uncertainties regarding the mechanism of action of anti-CD20 monoclonal antibody GA101
Autorzy :
Chien, Wei Wen
Niogret, Charlène
Jugé, Romain
Lionnard, Loïc
Cornut-Thibaut, Aurélie
Kucharczak, Jérôme
Savina, Ariel
Salles, Gilles
AOUACHERIA, Abdel
Pokaż więcej
Temat :
Antibody-based immunotherapy
CD20
Cathepsin B
Cell death
GA101
Lymphomas
Lysosomal permeabilization
MESH: Antibodies, Monoclonal/immunology
MESH: Antibodies, Monoclonal/pharmacology
MESH: Antibodies, Monoclonal, Humanized/therapeutic use
MESH: Antigens, CD20/immunology
MESH: Cathepsin B/immunology
MESH: Cell Death/drug effects
MESH: Cell Line, Tumor
MESH: Cross Reactions/immunology
MESH: Humans
MESH: Intracellular Membranes/metabolism
MESH: Leukemia, B-Cell/drug therapy
MESH: Lysosomes/ultrastructure
MESH: Mitochondrial Membranes/metabolism
MESH: Permeability/drug effects
MESH: Antibodies, Monoclonal/therapeutic use
MESH: Antibodies, Monoclonal, Humanized/pharmacokinetics
[SDV.IMM]Life Sciences [q-bio]/Immunology
[SDV.BC]Life Sciences [q-bio]/Cellular Biology
[SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy
[SDV.CAN]Life Sciences [q-bio]/Cancer
[SDV.BC.BC]Life Sciences [q-bio]/Cellular Biology/Subcellular Processes [q-bio.SC]
[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN]
[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology
[SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biomolecules [q-bio.BM]
[INFO.INFO-BT]Computer Science [cs]/Biotechnology
[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging
Źródło :
Leukemia Research, Elsevier, 2017, 55 (2), pp.41-48. ⟨10.1016/j.leukres.2017.01.010⟩
Tytuł :
Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers
Autorzy :
Dixon, William G
Hyrich, Kimme L
Mercer, Louise K
Askling, Johan
Raaschou, Pauline
Dreyer, Lene
Hetland, Merete Lund
Strangfeld, Anja
Zink, Angela
Mariette, Xavier
Finckh, Axel
Canhao, Helena
Iannone, Florenzo
Zavada, Jakub
Morel, Jacques
Gottenberg, Jacques-Eric
Listing, Joachim
Pokaż więcej
Temat :
Registries
Clinical and Epidemiological Research
Skin Neoplasms
Antibodies, Monoclonal, Humanized
Anti-TNF
Biological Products
Rituximab/therapeutic use
Tumor Necrosis Factor-alpha
Epidemiology
Antirheumatic Agents/therapeutic use
Arthritis, Rheumatoid/drug therapy
Antirheumatic Agents
Skin Neoplasms/epidemiology
Female
Europe
Rituximab
Risk Factors
Biological Products/therapeutic use
ddc:616
Abatacept
Aged
Melanoma
Middle Aged
Rheumatoid Arthritis
Melanoma/epidemiology
Abatacept/therapeutic use
Tumor Necrosis Factor-alpha/antagonists & inhibitors
Arthritis, Rheumatoid
Antibodies, Monoclonal, Humanized/therapeutic use
Europe/epidemiology
Journal Article
Adult
Aged, 80 and over
Humans
Incidence
Male
Źródło :
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, Vol. 76, No 2 (2017) pp. 386-391
Mercer, L K, Askling, J, Raaschou, P, Dixon, W G, Dreyer, L, Hetland, M L, Strangfeld, A, Zink, A, Mariette, X, Finckh, A, Canhao, H, Iannone, F, Zavada, J, Morel, J, Gottenberg, J-E, Hyrich, K L & Listing, J 2017, ' Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics : results from a collaborative project of 11 European biologic registers ', Annals of the Rheumatic Diseases, vol. 76, no. 2, pp. 386-391 . https://doi.org/10.1136/annrheumdis-2016-209285
Mercer, L, Askling, J, Raaschou, P, Dixon, W, Dreyer, L, Lund Hetland, M, Strangfeld, A, Zink, A, Mariette, X, Finckh, A, Canhao, H, Iannone, F, Zavada, J, Morel, J, Gottenberg, J-E, Hyrich, K & Listing, J 2016, ' Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers ', Annals of the rheumatic diseases . https://doi.org/10.1136/annrheumdis-2016-209285
Opis pliku :
application/pdf
Tytuł :
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study
Autorzy :
Gabay, C.
Riek, M.
Hetland, M.L.
Hauge, E.M.
Pavelka, K.
Tomsic, M.
Canhao, H.
Chatzidionysiou, K.
Lukina, G.
Nordstrom, D.C.
Lie, E.
Ancuta, I.
Hernandez, M.V.
Riel, P.L.C.M. van
Vollenhoven, R. van
Kvien, T.K.
Pokaż więcej
Temat :
DMARDs (biologic)
Treatment
MULTIPLE IMPUTATION
METHOTREXATE
ACT-RAY
ADDING TOCILIZUMAB
Clinical and Epidemiological Research
Antirheumatic Agents/therapeutic use
Arthritis, Rheumatoid/drug therapy
INADEQUATE RESPONSES
Drug Therapy, Combination
Female
Europe
DOUBLE-BLIND
CONTROLLED-STUDY SURPRISE
CONTROLLED-TRIAL
Middle Aged
Treatment Outcome
Rheumatoid Arthritis
3121 Internal medicine
DMARDs (synthetic)
Severity of Illness Index
RECEPTOR INHIBITION
MONOTHERAPY
Antibodies, Monoclonal, Humanized/therapeutic use
Journal Article
Humans
Male
Źródło :
Annals of the Rheumatic Diseases, 75(7), 1336 - 42. BMJ Publishing Group
Annals of the Rheumatic Diseases, 75, 1336 - 1342
Gabay, C, Riek, M, Hetland, M L, Hauge, E M, Pavelka, K, Tomšič, M, Canhao, H, Chatzidionysiou, K, Lukina, G, Nordström, D C, Lie, E, Ancuta, I, Hernández, M V, Van Riel, P L M C, Van Vollenhoven, R & Kvien, T K 2016, ' Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis : Results from a European collaborative study ', Annals of the Rheumatic Diseases, vol. 75, no. 7, pp. 1336-1342 . https://doi.org/10.1136/annrheumdis-2015-207760
Annals of the Rheumatic Diseases
Annals of the rheumatic diseases, 75(7), 1336 - 1342. BMJ Publishing Group
Tytuł :
Safety and feasibility of the use of a bevacizumab-methylcellulose mixture as an adjunct to glaucoma surgery: a pilot study
Segurança e viabilidade do uso de uma mistura de bevacizumabe-metilcelulose como terapia adjuvante à cirurgia anti-glaucomatosa: um estudo piloto
Autorzy :
Paula, Jayter Silva
Secches, Danilo José Lopes
Silva, Marcelo Jordão Lopes
Rodrigues, Maria de Lourdes Veronese
Cunha Junior, Armando da Silva
Pokaż więcej
Temat :
Trabeculectomy/adverse effects
Glaucoma/surgery
Sclerectomy
Antibodies, monoclonal, humanized/therapeutic use
Methylcellulose/therapeutic use
Mitomycin/therapeutic use
Chemotherapy, adjuvant
Intraocular pressure/physiology
Trabeculectomia/efeitos adversos
Glaucoma/cirurgia
Esclerostomia
Anticorpos monoclonais humanizados/uso terapêutico
Metilcelulose/uso terapêutico
Mitomicina/uso terapêutico
Quimioterapia adjuvante
Pressão intraocular/fisiologia
Źródło :
Arquivos Brasileiros de Oftalmologia, Volume: 78, Issue: 3, Pages: 194-196, Published: JUN 2015
Opis pliku :
text/html
Tytuł :
FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study
Autorzy :
Geva, Ravit
Vecchione, Loredana
Kalogeras, Konstantinos T
Vittrup Jensen, Benny
Lenz, Heinz-Josef
Yoshino, Takayuki
Paez, David
Montagut, Clara
Souglakos, John
Cappuzzo, Federico
Cervantes, Andrés
Frattini, Milo
Fountzilas, George
Johansen, Julia S
Høgdall, Estrid Vilma
Zhang, Wu
Yang, Dongyun
Yamazaki, Kentaro
Nishina, Tomohiro
Papamichael, Demetris
Vincenzi, Bruno
Macarulla, Teresa
Loupakis, Fotios
De Schutter, Jef
Spindler, Karen-Lise Garm
Pfeiffer, Per
Ciardiello, Fortunato
Piessevaux, Hubert
Tejpar, Sabine
Pokaż więcej
Temat :
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized/therapeutic use
Antineoplastic Agents/therapeutic use
Cetuximab
Colorectal Neoplasms/drug therapy
Disease-Free Survival
ErbB Receptors/antagonists & inhibitors
Female
Genotyping Techniques/standards
Germ-Line Mutation
Humans
Male
Middle Aged
Neoplasm Metastasis
Polymorphism, Genetic
Receptors, IgG/genetics
Survival Rate
Young Adult
Źródło :
Geva, R, Vecchione, L, Kalogeras, K T, Vittrup Jensen, B, Lenz, H-J, Yoshino, T, Paez, D, Montagut, C, Souglakos, J, Cappuzzo, F, Cervantes, A, Frattini, M, Fountzilas, G, Johansen, J S, Høgdall, E V, Zhang, W, Yang, D, Yamazaki, K, Nishina, T, Papamichael, D, Vincenzi, B, Macarulla, T, Loupakis, F, De Schutter, J, Spindler, K-L G, Pfeiffer, P, Ciardiello, F, Piessevaux, H & Tejpar, S 2015, ' FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study ', Gut, vol. 64, no. 6, pp. 921-928 . https://doi.org/10.1136/gutjnl-2014-307234

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies